mRNA Cell Therapy
Overcoming the Limitations of Existing Cell Therapies
Myeloid is focused on advancing its ATAK CAR monocytes, which are myeloid cells with innate immune receptor-inspired CARs to recognize and kill cancer. Additionally, Myeloid has streamlined manufacturing for its ATAK cell therapy candidates through a rapid, single-day cell process. This method provides significant advantages to the patient, contract development, and manufacturing organizations (CDMO) over allogeneic approaches.
Key Platform Characteristics
Empowering myeloid cells to produce anti-tumor agents and modify the tumor microenvironment.
Directing phagocytic properties of myeloid cells, including the capability to recognize and engulf cancer cells.
Harnessing the frequent migration of myeloid cells from the blood into solid tumors and sites of inflammation.
Bridging innate and adaptive immunity to elicit a broad anti-tumor immune response with tumor-specific T cells.